Objective: The objective of this study was to compare postoperative morphine equivalent (MEQ) intake after open abdominal aortic aneurysm repair among analgesic modalities: standard analgesia (SA) with systemic opioid administration, epidural analgesia (EA), and surgically positioned paravertebral catheter analgesia (PA).
Methods: A retrospective cohort study was performed of all open abdominal aortic aneurysm repairs from 2005 to 2016 at the QEII Health Science Center, Halifax, Nova Scotia. Total MEQ intake (on postoperative day [POD] 1, 2, and 3), time in intensive care, and adverse events were compared between patients with SA, EA, and PA. A multivariable zero inflated Poisson regression was used to determine the association between analgesic modality and MEQ. Multivariable logistic regression models were used to determine associations between analgesic modality and rates of discharge from intensive care within 1 day and adverse events. Adjusting covariates included age, comorbidities, smoking, American Society of Anesthesiologists status, presence of symptoms, anatomic candidacy for endovascular repair, and surgical approach (transperitoneal vs retroperitoneal).
Results: The final study cohort included 355 patients: 177 retroperitoneal and 178 transperitoneal repairs; 117 patients underwent PA, 65 EA, and 173 SA. Compared with SA, PA and EA were associated with decreased MEQ intake on POD 1, 2, and 3 (Table I) . Compared with SA, PA and EA were associated with decreased odds of receiving opioids on POD 1, 2, and 3 (Table II) . If patients did receive opioids, compared with SA, PA and EA were associated with decreased consumption on POD 1 (Table II) . Compared with SA, PA was associated with earlier discharge from intensive care (odds ratio, 2.75; 95% confidence interval, 1.17-6.45). Compared with EA, PA was not associated with increased odds of adverse events (odds ratio, 0.44; 95% confidence interval, 0.08-2.44).
Conclusions: PA and EA are associated with decreased MEQ intake compared with SA. PA is associated with earlier discharge from intensive care compared with SA and similar rates of adverse events compared with EA.
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